{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":37,"n_cols":5,"rows_kept":37,"merged":[[1,0,1,4],[7,0,7,4],[13,0,13,4],[19,0,19,4],[25,0,25,4],[31,0,31,4]],"flags":["formulas_cached_only"]}
["#","TFs","GO processes","Root nodes","p-value"]
["1D-"]
[1,"c-Myc","RNA splicing (15.2%; 2.080e-05), mRNA processing (15.2%; 4.334e-05), nuclear mRNA splicing, via spliceosome (10.9%; 1.199e-04), RNA splicing, via transesterification reactions (10.9%; 1.199e-04), RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (10.9%; 1.199e-04)",45,{"v":6.82e-116,"d":"6.820E-116"}]
[2,"HNF4-alpha","RNA splicing (15.2%; 3.350e-04), mRNA processing (15.2%; 5.664e-04), mRNA metabolic process (15.2%; 1.205e-03), primary metabolic process (72.7%; 3.397e-03), regulation of homocysteine metabolic process (3.0%; 3.934e-03)",32,{"v":1.2599999999999997e-81,"d":"1.260E-81"}]
[3,"SP1","interspecies interaction between organisms (16.1%; 9.376e-04), negative regulation of defense response to virus (3.2%; 1.850e-03), negative regulation of multi-organism process (3.2%; 1.850e-03), peptidyl-aspartic acid hydroxylation (3.2%; 1.850e-03), peptidyl-aspartic acid modification (3.2%; 1.850e-03)",30,{"v":2.0799999999999995e-76,"d":"2.080E-76"}]
[4,"ESR1 (nuclear)","response to estrogen stimulus (15.0%; 1.484e-03), response to endogenous stimulus (25.0%; 1.493e-03), protein amino acid methylation (10.0%; 1.602e-03), protein amino acid alkylation (10.0%; 1.602e-03), pancreas development (10.0%; 1.731e-03)",19,{"v":5.4199999999999995e-48,"d":"5.420E-48"}]
[5,"p53","positive regulation of cellular biosynthetic process (37.5%; 1.845e-04), positive regulation of biosynthetic process (37.5%; 2.006e-04), response to X-ray (12.5%; 2.531e-04), cell cycle (37.5%; 2.641e-04), organelle organization (43.8%; 4.478e-04)",15,{"v":8.859999999999999e-38,"d":"8.860E-38"}]
["1D+"]
[1,"c-Myc","translational elongation (29.2%; 7.504e-10), translation (29.2%; 1.165e-06), cellular macromolecular complex subunit organization (25.0%; 1.038e-04), cellular biosynthetic process (62.5%; 1.147e-04), biosynthetic process (62.5%; 1.534e-04)",23,{"v":1.4299999999999997e-63,"d":"1.430E-63"}]
[2,"SP1","regulation of cell morphogenesis (19.0%; 8.406e-05), regulation of cell shape (14.3%; 1.080e-04), muscle contraction (19.0%; 1.376e-04), cell differentiation (47.6%; 1.394e-04), myoblast fusion (9.5%; 1.555e-04)",20,{"v":4.23e-55,"d":"4.230E-55"}]
[3,"MYOD","muscle contraction (50.0%; 8.309e-08), muscle system process (50.0%; 1.087e-07), striated muscle contraction (40.0%; 1.593e-07), muscle organ development (40.0%; 3.476e-05), muscle filament sliding (20.0%; 3.828e-05)",9,{"v":1.4900000000000002e-24,"d":"1.490E-24"}]
[4,"GATA-1","cellular biosynthetic process (87.5%; 3.883e-04), biosynthetic process (87.5%; 4.555e-04), spermatocyte division (12.5%; 4.774e-04), germ-line cyst formation (12.5%; 9.545e-04), drug catabolic process (12.5%; 9.545e-04)",8,{"v":8.020000000000001e-22,"d":"8.020E-22"}]
[5,"ESR1 (nuclear)","nitrogen compound biosynthetic process (50.0%; 5.981e-06), cellular nitrogen compound metabolic process (50.0%; 1.748e-05), purine ribonucleoside triphosphate biosynthetic process (37.5%; 2.841e-05), purine nucleoside triphosphate biosynthetic process (37.5%; 2.904e-05), ribonucleoside triphosphate biosynthetic process (37.5%; 2.904e-05)",7,{"v":4.22e-19,"d":"4.220E-19"}]
["4D-"]
[1,"c-Myc","intracellular transport (27.6%; 7.310e-05), cellular macromolecular complex assembly (20.7%; 1.975e-04), nitrogen compound metabolic process (58.6%; 2.114e-04), cellular component biogenesis (31.0%; 2.993e-04), cellular macromolecular complex subunit organization (20.7%; 3.183e-04)",28,{"v":1.4799999999999997e-73,"d":"1.480E-73"}]
[2,"SP1","muscle contraction (22.2%; 1.037e-06), muscle system process (22.2%; 1.419e-06), striated muscle contraction (14.8%; 1.242e-05), fructose 1,6-bisphosphate metabolic process (7.4%; 3.734e-05), glycolysis (11.1%; 8.279e-05)",26,{"v":3.4699999999999992e-68,"d":"3.470E-68"}]
[3,"HNF4-alpha","RNA splicing (14.8%; 1.475e-03), cardiac muscle contraction (7.4%; 1.785e-03), heart contraction (7.4%; 2.167e-03), heart process (7.4%; 2.167e-03), mRNA processing (14.8%; 2.244e-03)",26,{"v":3.4699999999999992e-68,"d":"3.470E-68"}]
[4,"ESR1 (nuclear)","fructose 1,6-bisphosphate metabolic process (11.8%; 1.449e-05), glycolysis (17.6%; 1.968e-05), glucose catabolic process (17.6%; 3.642e-05), hexose catabolic process (17.6%; 5.822e-05), monosaccharide catabolic process (17.6%; 8.718e-05)",16,{"v":1.32e-41,"d":"1.320E-41"}]
[5,"p53","response to X-ray (16.7%; 1.397e-04), positive regulation of lipid biosynthetic process (16.7%; 2.921e-04), positive regulation of cellular biosynthetic process (41.7%; 3.704e-04), positive regulation of biosynthetic process (41.7%; 3.976e-04), mitochondrial membrane organization (16.7%; 4.176e-04)",11,{"v":1.66e-28,"d":"1.660E-28"}]
["4D+"]
[1,"c-Myc","translational elongation (21.1%; 7.676e-10), translation (26.3%; 1.685e-08), ribosomal small subunit biogenesis (7.9%; 7.155e-06), cellular metabolic process (81.6%; 7.943e-06), cellular biopolymer metabolic process (68.4%; 2.777e-05)",37,{"v":2.5799999999999996e-100,"d":"2.580E-100"}]
[2,"ESR1 (nuclear)","response to estrogen stimulus (27.3%; 2.318e-04), nitrogen compound biosynthetic process (27.3%; 7.787e-04), drug catabolic process (9.1%; 1.312e-03), exogenous drug catabolic process (9.1%; 1.312e-03), peptidyl-cysteine S-nitrosylation (9.1%; 1.312e-03)",10,{"v":1.82e-26,"d":"1.820E-26"}]
[3,"HIF1A","embryonic placenta development (20.0%; 9.878e-04), response to bacterial lipoprotein (10.0%; 1.789e-03), sequestering of calcium ion (10.0%; 2.385e-03), elastin metabolic process (10.0%; 2.385e-03), inflammatory response (30.0%; 2.632e-03)",9,{"v":8.190000000000001e-24,"d":"8.190E-24"}]
[4,"GATA-1","cellular biosynthetic process (88.9%; 1.089e-04), biosynthetic process (88.9%; 1.308e-04), spermatocyte division (11.1%; 5.370e-04), erythrocyte differentiation (22.2%; 5.903e-04), multicellular organismal development (77.8%; 6.787e-04)",9,{"v":8.190000000000001e-24,"d":"8.190E-24"}]
[5,"p53","negative regulation of cellular process (77.8%; 1.757e-05), negative regulation of biological process (77.8%; 3.150e-05), response to oxygen levels (33.3%; 2.608e-04), response to chemical stimulus (66.7%; 3.814e-04), DNA damage checkpoint (22.2%; 4.317e-04)",8,{"v":3.62e-21,"d":"3.620E-21"}]
["7D-"]
[1,"SP1","muscle contraction (22.2%; 1.037e-06), muscle system process (22.2%; 1.419e-06), striated muscle contraction (14.8%; 1.242e-05), actin filament-based movement (11.1%; 3.030e-05), fructose 1,6-bisphosphate metabolic process (7.4%; 3.734e-05)",26,{"v":9.269999999999998e-70,"d":"9.270E-70"}]
[2,"c-Myc","regulation of ATPase activity (7.7%; 4.773e-04), sarcomere organization (7.7%; 1.259e-03), translational elongation (11.5%; 1.289e-03), cellular biosynthetic process (53.8%; 1.568e-03), intracellular transport (23.1%; 1.656e-03)",25,{"v":5.1699999999999995e-67,"d":"5.170E-67"}]
[3,"ESR1 (nuclear)","fructose 1,6-bisphosphate metabolic process (14.3%; 9.702e-06), glycolysis (21.4%; 1.061e-05), glucose catabolic process (21.4%; 1.966e-05), hexose catabolic process (21.4%; 3.147e-05), monosaccharide catabolic process (21.4%; 4.720e-05)",13,{"v":1.7999999999999998e-34,"d":"1.800E-34"}]
[4,"p53","nucleic acid-protein covalent cross-linking (12.5%; 4.774e-04), RNA-protein covalent cross-linking (12.5%; 4.774e-04), regulation of vitamin D receptor signaling pathway (12.5%; 9.545e-04), response to vitamin B3 (12.5%; 1.431e-03), negative regulation of helicase activity (12.5%; 1.431e-03)",7,{"v":1.5700000000000001e-18,"d":"1.570E-18"}]
[5,"Androgen receptor","cell growth (28.6%; 3.875e-04), male somatic sex determination (14.3%; 4.177e-04), activation of prostate induction by androgen receptor signaling pathway (14.3%; 4.177e-04), regulation of homocysteine metabolic process (14.3%; 8.352e-04), somatic sex determination (14.3%; 8.352e-04)",6,{"v":6.62e-16,"d":"6.620E-16"}]
["7D+"]
[1,"c-Myc","translation (26.1%; 6.798e-10), translational elongation (17.4%; 3.872e-09), cellular metabolic process (82.6%; 3.878e-07), cellular macromolecular complex subunit organization (21.7%; 2.036e-06), RNA processing (21.7%; 3.964e-06)",45,{"v":5.689999999999999e-118,"d":"5.690E-118"}]
[2,"SP1","system development (53.6%; 3.645e-05), anatomical structure development (53.6%; 6.951e-05), multicellular organismal development (53.6%; 3.363e-04), cellular protein complex assembly (14.3%; 4.945e-04), nitric oxide biosynthetic process (7.1%; 5.020e-04)",27,{"v":8.959999999999999e-70,"d":"8.960E-70"}]
[3,"HNF4-alpha","ribosomal small subunit biogenesis (10.7%; 2.796e-06), translational elongation (17.9%; 3.188e-06), RNA metabolic process (32.1%; 5.850e-05), RNA processing (21.4%; 3.875e-04), cellular metabolic process (78.6%; 4.829e-04)",27,{"v":8.959999999999999e-70,"d":"8.960E-70"}]
[4,"ESR1 (nuclear)","response to estrogen stimulus (26.7%; 2.107e-05), response to steroid hormone stimulus (26.7%; 3.062e-04), peptide cross-linking (13.3%; 3.652e-04), developmental process (66.7%; 6.334e-04), anatomical structure development (60.0%; 6.984e-04)",14,{"v":8.23e-36,"d":"8.230E-36"}]
[5,"p53","regulation of developmental process (60.0%; 4.987e-06), cell cycle (46.7%; 1.447e-05), regulation of apoptosis (46.7%; 1.639e-05), regulation of programmed cell death (46.7%; 1.775e-05), regulation of cell death (46.7%; 1.808e-05)",14,{"v":8.23e-36,"d":"8.230E-36"}]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}